Literature DB >> 10830921

Characterization of von Willebrand factor in primary pulmonary hypertension.

M T Collados1, J Sandoval, S López, F A Massó, A Páez, J R Borbolla, L F Montaño.   

Abstract

The aim of this study was to determine the value of von Willebrand factor (vWF), a well-characterized endothelial cell protein secretion, as a marker for prognosis in patients with primary pulmonary hypertension (PPH). Venous and arterial blood samples were obtained from 18 clinically diagnosed PPH patients and 12 case controls matched for age and sex. Plasma vWF antigen was determined by enzyme-linked immunosorbent assay (ELISA). The patients' multimeric vWF pattern was analyzed by sodium dodecylsulfate (SDS)-agarose-acrylamide electrophoresis, Western blot, and densitometric analysis. vWF sialic acid content was determined by a lectin-based ELISA. The PPH patients showed a higher content of vWF antigen in venous (P = 0.0026) and arterial (P = 0.0094) blood samples than controls. The mean vWF sialic acid content of the PPH patients corresponded to 37.7% of the mean value for the control group. On the basis of the hemodynamic response to vasodilator trial, the PPH patients were grouped as responders or nonresponders. The latter group showed a significantly higher plasma vWF antigen antecubital vein/radial artery ratio, an increased number of unusually large vWF multimers, and a diminished content of vWF sialic acid in comparison with the first group. We believe that our results establish the nature of vWF alterations that are related to endothelial cell damage in patients with primary pulmonary hypertension and that this could be of value when establishing the prognosis in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10830921     DOI: 10.1007/bf01747854

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  45 in total

1.  Haemodynamic effects of slow-release nifedipine in severe congestive heart failure due to ischaemic heart disease.

Authors:  A Rossi; V Ziacchi
Journal:  Cardiology       Date:  1990       Impact factor: 1.869

Review 2.  Endothelium and atherosclerosis.

Authors:  L Badimon; J J Badimon; W Penny; M W Webster; J H Chesebro; V Fuster
Journal:  J Hypertens Suppl       Date:  1992-04

Review 3.  von Willebrand factor and cardiovascular disease.

Authors:  L Badimon; J J Badimon; J H Chesebro; V Fuster
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

Review 4.  Sialic acids as ligands in recognition phenomena.

Authors:  A Varki
Journal:  FASEB J       Date:  1997-03       Impact factor: 5.191

5.  Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor.

Authors:  B Samor; J C Michalski; C Mazurier; M Goudemand; P De Waard; J F Vliegenthart; G Strecker; J Montreuil
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

6.  Relevance of sialoglycoconjugates in murine thymocytes during maturation and selection in the thymus.

Authors:  G Alvarez; R Lascurain; A Pérez; P Degand; L F Montaño; S Martínez-Cairo; E Zenteno
Journal:  Immunol Invest       Date:  1999-01       Impact factor: 3.657

7.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

8.  Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension.

Authors:  A A Lopes; N Y Maeda
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 9.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

10.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

Authors:  D J Stewart; R D Levy; P Cernacek; D Langleben
Journal:  Ann Intern Med       Date:  1991-03-15       Impact factor: 25.391

View more
  5 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

2.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

Review 3.  Endothelial cells in the pathogenesis of pulmonary arterial hypertension.

Authors:  Colin E Evans; Nicholas D Cober; Zhiyu Dai; Duncan J Stewart; You-Yang Zhao
Journal:  Eur Respir J       Date:  2021-09-02       Impact factor: 33.795

Review 4.  An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.

Authors:  Joana Santos-Gomes; Inês Gandra; Rui Adão; Frédéric Perros; Carmen Brás-Silva
Journal:  Front Cardiovasc Med       Date:  2022-07-14

5.  Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension.

Authors:  Narendra Dereddy; Jing Huang; Markus Erb; Sibel Guzel; John H Wolk; Suvro S Sett; Michael H Gewitz; Rajamma Mathew
Journal:  Pulm Circ       Date:  2012-10       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.